BEYOND-PSA, which has been launched by Prostate Cancer Research and Nuffield Health, will evaluate how the Stockholm3 blood-based risk assessment test can be integrated into UK clinical pathways.

Dr Jayne Spink, chief scientific officer at Prostate Cancer Research, said: ‘Men cannot benefit from innovation that sits on a shelf. If we want to know whether Stockholm3 can help detect more cancers earlier in the UK, we must put it to work within real clinical pathways and measure the impact. BEYOND-PSA will provide the scale of evidence needed to understand what this approach could mean for patients, clinicians and the health system.'

Research in Europe on more than 12,000 men aged 50 to 74 found the test identified up to 90% of clinically significant prostate cancers compared with rates of 42% detected using standard screening methods, which measure prostate-specific antigen and assess risk using age-adjusted thresholds.

To support equitable access, the Stockholm3 test will be made available through Nuffield Health's enhanced screening programme at a subsidised cost of £99. Prostate Cancer Research has also established a limited philanthropic fund to support equitable access initiatives associated with the programme.